On October 14, 2026, Iambic Therapeutics, a San Diego drug developer built around its own AI models, priced its initial public offering of 9,375,000 shares at $16.00 each, for gross proceeds of $150 million, according to its final prospectus filed with the SEC on October 15. The stock was approved for listing on the Nasdaq Global Select Market under the symbol IAM. J.P. Morgan, Jefferies, BofA Securities and Citigroup led the offering, and existing investor ARK Investment Management and Duquesne Family Office indicated interest in buying up to $60 million of the shares. A Form 8-K filed October 16 confirms the IPO closed.
The prospectus describes Iambic as integrating “proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation,” an approach it calls “molecular superintelligence.” Its tools include Enchant, a multimodal model that predicts preclinical and clinical properties of molecules, and NeuralPLexer, a flow-matching generative model for biomolecular structure prediction. Automated plate-based chemistry and biology let it make and test hundreds of compounds per program each week, and the platform learns from that stream of lab data.
Its most advanced program, IAM1363, is an oral, brain-penetrant HER2 inhibitor that, as of September 2026, was in a Phase 1/1b trial in patients with advanced HER2-altered solid tumors; the company says it could start a registrational trial as early as 2027, subject to regulatory feedback.
Why it matters: public investors are being asked to put a price on AI-designed medicines before any has been approved. A completed $150 million listing, with anchor interest covering up to 40 percent of the deal, signals that the market is open to AI drug discovery stories that come with clinical data.
What it does not show: the prospectus itself states the approach is “novel and unproven” and has not yet led to an approved drug. An IPO price is a financing event, not evidence that AI-discovered molecules succeed more often in trials.